# Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

> **NCT06190067** · PHASE2 · RECRUITING · sponsor: **Navy General Hospital, Beijing** · enrollment: 40 (estimated)

## Conditions studied

- Relapsed Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** Azacitidine Plus PD-1 therapy

## Key facts

- **NCT ID:** NCT06190067
- **Lead sponsor:** Navy General Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06190067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06190067, "Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06190067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*